Celecoxib and Recombinant Interferon Alfa-2b in Metastatic Kidney Cancer Who Have Undergone Surgery

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

September 30, 2010

Study Completion Date

October 31, 2010

Conditions

Renal Cell CancerStage IV Renal Cell Cancer

Interventions

DRUG

celecoxib

Given orally

BIOLOGICAL

recombinant interferon alfa-2b

Given subcutaneously

OTHER

polymerase chain reaction

Correlative studies

OTHER

laboratory biomarker analysis

Correlative studies

OTHER

reverse transcriptase-polymerase chain reaction

Correlative studies

OTHER

immunologic technique

Correlative studies

OTHER

immunohistochemistry staining method

Correlative studies

OTHER

flow cytometry

Correlative studies

Trial Locations (1)

Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors

lead

Case Comprehensive Cancer Center

OTHER

NCT01158534 - Celecoxib and Recombinant Interferon Alfa-2b in Metastatic Kidney Cancer Who Have Undergone Surgery | Biotech Hunter | Biotech Hunter